Vertex Pharmaceuticals Inc
VRTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000875320
No open-market purchases or sales by Vertex Pharmaceuticals Inc insiders were filed in the last 90 days; 1,762 institutions reported holding it in 13F filings for Q2 2026, worth $119.7B in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Vertex Pharmaceuticals Inc as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 1,563
- +45 vs. Q3 2024
- Shares held
- 236.5M
- +1.92M (+0.8%) vs. Q3 2024
- Total value
- $95.2B
- −$13.7B (−12.6%) vs. Q3 2024
- New holders
- 200
- 553 more added
- Sold out
- 155
- 619 more reduced
33 institutions that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting VRTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1,762 | $119.7B |
| Q1 2026 | 1,698 | $106.1B |
| Q4 2025 | 1,671 | $109.5B |
| Q3 2025 | 1,523 | $90.8B |
| Q2 2025 | 1,563 | $107.2B |
| Q1 2025 | 1,617 | $116.3B |
| Q4 2024 | 1,563 | $95.2B |
| Q3 2024 | 1,551 | $109.1B |
| Q2 2024 | 1,551 | $109.9B |
| Q1 2024 | 1,497 | $98.0B |
| Q4 2023 | 1,442 | $95.7B |
| Q3 2023 | 1,280 | $81.9B |
| Q2 2023 | 1,287 | $83.3B |
| Q1 2023 | 1,212 | $75.0B |
| Q4 2022 | 1,224 | $68.3B |
| Q3 2022 | 1,127 | $68.5B |
| Q2 2022 | 1,109 | $66.1B |
| Q1 2022 | 1,072 | $60.9B |
| Q4 2021 | 1,034 | $50.4B |
| Q3 2021 | 936 | $41.9B |
| Q2 2021 | 979 | $46.8B |
| Q1 2021 | 1,000 | $50.6B |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Vertex Pharmaceuticals Inc; share changes are against Q3 2024.